Three newly released studies suggest a potential role for tocilizumab in COVID-19 but do not provide enough evidence of efficacy to support routine use of the drug, experts say. Published in JAMA Internal Medicine, the three trials – two of them RCTs – fail to confirm the positive results seen with the IL-6 inhibitor in ...
Tocilizumab fails to convince in three new COVID-19 trials
By Michael Woodhead
21 Oct 2020